U.S. Markets closed

Sarepta Hit With Call to Drop Duchenne Drug Costs

Bill Meagher

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.